United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Apr 26, 2012
United Therapeutics Corporation Reports First Quarter 2012 Financial Results

Apr 19, 2012
United Therapeutics Corporation To Announce First Quarter 2012 Financial Results Before Market Open On Thursday, April 26, 2012

more »

Events

Jun 4, 2012
Jefferies 2012 Global Healthcare Conference in New York City

Jul 31, 2012
BMO Capital Corporate Access Days

more »